SLC5A2 and type 2 diabetes mellitus: Specifically, in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME trial) SGLT2 inhibitor empagliflozin reduced the risk of progression to macroalbuminuria, a doubling of the serum creatinine, initiation of renal replacement therapy or death from renal disease in patients with type 2 diabetes [10].